Pain Management Therapeutics Market Size to HIt USD 127.78 billion by 2035

Chapter 1. Introduction

1.1. Research Objective
1.2. Scope of the Study
1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach
2.2. Data Sources
2.3. Assumptions& Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Pain Management Therapeutics Market Variables and Scope

4.1. Introduction
4.2. Market Classification and Scope

Chapter 5. COVID 19 Impact on Pain Management Therapeutics Market

5.1. Covid-19: Pain Management Therapeutics Industry Impact
5.2. Pain Management Therapeutics Business Impact Assessment: Covid-19
5.2.1. Services Challenges/Disruption
5.2.2. Market Trends and Pain Management Therapeutics Opportunities in the COVID-19 Landscape for Major Markets
5.3. Strategic Measures against Covid-19
5.3.1. Government Support and Initiative to Combat Covid-19
5.3.2. Proposal for Pain Management Therapeutics Market Players to deal with Covid-19 Pandemic Scenario

Chapter 6. Pain Management Therapeutics Market Dynamics Analysis and Trends

6.1. Market Dynamics
6.1.1. Market Drivers
6.1.1.1. Growing prevalence of chronic disorders
6.1.1.2. Increasing geriatric population
6.1.2. Market Restraints
6.1.2.1. Side-effects associated with some pain management medications
6.1.3. Market Opportunities
6.1.3.1. Growing research and development expenditure
6.1.3.2. Technological advancements

Chapter 7. Global Pain Management Therapeutics Market: Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis
7.1.1.1. Pain Management Therapeutics Market Revenue by Market Players
7.1.1.2. Pain Management Therapeutics Market Revenue Market Share by Market Players
7.1.2. Key Organic/Inorganic Strategies Adopted by Players
7.1.2.1. Product Portfolio Expansion, Geographic Expansion, Drug Class Innovation
7.1.2.2. Merger and Acquisition, Collaboration and Partnerships
7.1.3. Market Players Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of End-users

Chapter 8. Global Pain Management Therapeutics Market, By Drug Class

8.1. Pain Management Therapeutics Market, by Drug Class
8.1.1. NSAIDs
8.1.1.1. Market Revenue and Forecast
8.1.2. Opioids
8.1.2.1. Market Revenue and Forecast
8.1.3. Anesthetics
8.1.3.1. Market Revenue and Forecast
8.1.4. Antidepressants
8.1.4.1. Market Revenue and Forecast
8.1.5. Anticonvulsants
8.1.5.1. Market Revenue and Forecast
8.1.6. Others
8.1.6.1. Market Revenue and Forecast

Chapter 9. Global Pain Management Therapeutics Market, By Indication

9.1. Pain Management Therapeutics Market, by Indication
9.1.1. Arthritic Pain
9.1.1.1. Market Revenue and Forecast
9.1.2. Neuropathic Pain
9.1.2.1. Market Revenue and Forecast
9.1.3. Chronic Back Pain
9.1.3.1. Market Revenue and Forecast
9.1.4. Post-Operative Pain
9.1.4.1. Market Revenue and Forecast
9.1.5. Cancer Pain
9.1.5.1. Market Revenue and Forecast
9.1.6. Others
9.1.6.1. Market Revenue and Forecast

Chapter 10. Global Pain Management Therapeutics Market, By Distribution Channel

10.1. Pain Management Therapeutics Market, by Distribution Channel
10.1.1. Online Pharmacy
10.1.1.1. Market Revenue and Forecast
10.1.2. Retail Pharmacy
10.1.2.1. Market Revenue and Forecast
10.1.3. Hospital Pharmacy
10.1.3.1. Market Revenue and Forecast

Chapter 11. Global Pain Management Therapeutics Market, Regional Estimates and Trend Forecast

11.1. North America
11.1.1. Market Revenue Forecast by Drug Class
11.1.2. Market Revenue Forecast by Indication
11.1.3. Market Revenue Forecast by Distribution Channel
11.1.4. U.S
11.1.4.1. Market Revenue Forecast
11.1.5. Canada
11.1.5.1. Market Revenue Forecast
11.2. Europe
11.2.1. Market Revenue Forecast by Drug Class
11.2.2. Market Revenue Forecast by Indication
11.2.3. Market Revenue Forecast by Distribution Channel
11.2.4. UK
11.2.4.1. Market Revenue Forecast
11.2.5. Germany
11.2.5.1. Market Revenue Forecast
11.2.6. France
11.2.6.1. Market Revenue Forecast
11.2.7. Rest of EU
11.2.7.1. Market Revenue Forecast
11.3. Asia Pacific (APAC)
11.3.1. Market Revenue Forecast by Drug Class
11.3.2. Market Revenue Forecast by Indication
11.3.3. Market Revenue Forecast by Distribution Channel
11.3.4. China
11.3.4.1. Market Revenue Forecast
11.3.5. India
11.3.5.1. Market Revenue Forecast
11.3.6. Japan
11.3.6.1. Market Revenue Forecast
11.3.7. Rest of APAC
11.3.7.1. Market Revenue Forecast
11.4. LATAM
11.4.1. Market Revenue Forecast by Drug Class
11.4.2. Market Revenue Forecast by Indication
11.4.3. Market Revenue Forecast by Distribution Channel
11.4.4. Brazil
11.4.4.1. Market Revenue Forecast
11.4.5. Rest of LATAM
11.4.5.1. Market Revenue Forecast
11.5. Middle East and Africa (MEA)
11.5.1. Market Revenue Forecast by Drug Class
11.5.2. Market Revenue Forecast by Indication
11.5.3. Market Revenue Forecast by Distribution Channel
11.5.4. GCC
11.5.4.1. Market Revenue Forecast
11.5.5. North Africa
11.5.5.1. Market Revenue Forecast
11.5.6. South Africa
11.5.6.1. Market Revenue Forecast
11.5.7. Rest of MEA
11.5.7.1. Market Revenue Forecast

Chapter 12. Company Profiles

12.1. Teva Pharmaceutical
12.1.1. Company Overview, Business Information, Regional Presence
12.1.2. Product Portfolio Analysis
12.1.2.1. Product Details, Specification, Distribution Channel
12.1.3. Revenue, Price, and Gross Margin
12.1.4. Recent Developments and Strategies
12.2. Pfizer
12.2.1. Company Overview, Business Information, Regional Presence
12.2.2. Product Portfolio Analysis
12.2.2.1. Product Details, Specification, Distribution Channel
12.2.3. Revenue, Price, and Gross Margin
12.2.4. Recent Developments and Strategies
12.3. Abbott
12.3.1. Company Overview, Business Information, Regional Presence
12.3.2. Product Portfolio Analysis
12.3.2.1. Product Details, Specification, Distribution Channel
12.3.3. Revenue, Price, and Gross Margin
12.3.4. Recent Developments and Strategies
12.4. Mallinckrodt Pharmaceuticals
12.4.1. Company Overview, Business Information, Regional Presence
12.4.2. Product Portfolio Analysis
12.4.2.1. Product Details, Specification, Distribution Channel
12.4.3. Revenue, Price, and Gross Margin
12.4.4. Recent Developments and Strategies
12.5. Endo International
12.5.1. Company Overview, Business Information, Regional Presence
12.5.2. Product Portfolio Analysis
12.5.2.1. Product Details, Specification, Distribution Channel
12.5.3. Revenue, Price, and Gross Margin
12.5.4. Recent Developments and Strategies
12.6. GlaxoSmithKline
12.6.1. Company Overview, Business Information, Regional Presence
12.6.2. Product Portfolio Analysis
12.6.2.1. Product Details, Specification, Distribution Channel
12.6.3. Revenue, Price, and Gross Margin
12.6.4. Recent Developments and Strategies
12.7. AstraZeneca
12.7.1. Company Overview, Business Information, Regional Presence
12.7.2. Product Portfolio Analysis
12.7.2.1. Product Details, Specification, Distribution Channel
12.7.3. Revenue, Price, and Gross Margin
12.7.4. Recent Developments and Strategies
12.8. Depomed
12.8.1. Company Overview, Business Information, Regional Presence
12.8.2. Product Portfolio Analysis
12.8.2.1. Product Details, Specification, Distribution Channel
12.8.3. Revenue, Price, and Gross Margin
12.8.4. Recent Developments and Strategies
12.9. Merck
12.9.1. Company Overview, Business Information, Regional Presence
12.9.2. Product Portfolio Analysis
12.9.2.1. Product Details, Specification, Distribution Channel
12.9.3. Revenue, Price, and Gross Margin
12.9.4. Recent Developments and Strategies
12.10. Novartis
12.10.1. Company Overview, Business Information, Regional Presence
12.10.2. Product Portfolio Analysis
12.10.2.1. Product Details, Specification, Distribution Channel
12.10.3. Revenue, Price, and Gross Margin
12.10.4. Recent Developments and Strategies

Chapter 13. Appendix

13.1. About Us
13.2. Glossary of Terms

For questions or customization requests, please reach out to us at sales@precedenceresearch.com

Frequently Asked Questions

Answer : The pain management therapeutics market size was evaluated at USD 88.19 billion in 2025 and is anticipated to hit over USD 127.78 billion by 2035.

Answer : The pain management therapeutics domain includes the contraction and treatment of pain with the use of various groupings of drugs and workouts which deliver relief to the sufferer by directing at the receptors. The demand for pain management has seen an exponential rise mainly due to changing lifestyle patterns and growing number of chronic ailments.

Answer : The global pain management therapeutics market is expected to drive growth at a CAGR of 3.78% during the forecast period 2026 to 2035.

Answer : Factors such as increasing geriatric population, rising number of accidents worldwide, growing prevalence of chronic disorders, rise in per-capita healthcare expenditure, increasing number of surgeries, constant approvals for new easy-to-use and effective medications, increasing cases of cancer in developing regions, and growing research and development expenditure are propelling the pain management therapeutics market expansion across the globe.

Answer : North America accounted for the largest pain management therapeutics market share in 2025